Compare Stocks: ANNX, DNLI, VCYT, and GRAL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$4.87 +0.6%	$5.38	$2.10 ▼ $7.18	$923.25M	1.21	2.44 million shs	1.23 million shs
DNLI Denali Therapeutics	$22.28 -2.3%	$24.44	$12.58 ▼ $27.30	$3.56B	1.01	1.18 million shs	799,584 shs
GRAL GRAIL	$80.34 -0.3%	$72.54	$33.61 ▼ $118.84	$3.59B	3.25	706,798 shs	434,331 shs
VCYT Veracyte	$42.53 -4.8%	$50.64	$29.45 ▼ $60.91	$3.42B	1.93	1.23 million shs	992,031 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	0.00%	-2.01%	-13.04%	-7.94%	+137.56%
DNLI Denali Therapeutics	0.00%	-7.17%	-9.91%	+14.14%	+45.53%
GRAL GRAIL	0.00%	+0.43%	+26.72%	+33.94%	+147.81%
VCYT Veracyte	0.00%	-1.87%	-7.84%	-12.72%	+38.90%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$4.87 +0.6%	$5.38	$2.10 ▼ $7.18	$923.25M	1.21	2.44 million shs	1.23 million shs
DNLI Denali Therapeutics	$22.28 -2.3%	$24.44	$12.58 ▼ $27.30	$3.56B	1.01	1.18 million shs	799,584 shs
GRAL GRAIL	$80.34 -0.3%	$72.54	$33.61 ▼ $118.84	$3.59B	3.25	706,798 shs	434,331 shs
VCYT Veracyte	$42.53 -4.8%	$50.64	$29.45 ▼ $60.91	$3.42B	1.93	1.23 million shs	992,031 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	0.00%	-2.01%	-13.04%	-7.94%	+137.56%
DNLI Denali Therapeutics	0.00%	-7.17%	-9.91%	+14.14%	+45.53%
GRAL GRAIL	0.00%	+0.43%	+26.72%	+33.94%	+147.81%
VCYT Veracyte	0.00%	-1.87%	-7.84%	-12.72%	+38.90%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	2.40	Hold	$15.14	210.94% Upside
DNLI Denali Therapeutics	2.76	Moderate Buy	$35.85	60.89% Upside
GRAL GRAIL	2.30	Hold	$67.78	-15.64% Downside
VCYT Veracyte	2.82	Moderate Buy	$54.33	27.75% Upside

Current Analyst Ratings Breakdown

Latest ANNX, DNLI, VCYT, and GRAL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	ANNX Annexon	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$10.00 ➝ $14.00
8/25/2026	DNLI Denali Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$30.00 ➝ $35.00
8/24/2026	VCYT Veracyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
8/13/2026	ANNX Annexon	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform
8/11/2026	VCYT Veracyte	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/7/2026	VCYT Veracyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/7/2026	DNLI Denali Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$25.00 ➝ $34.00
8/7/2026	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$34.00
8/4/2026	VCYT Veracyte	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$66.00 ➝ $54.00
8/4/2026	VCYT Veracyte	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$68.00 ➝ $55.00
8/4/2026	VCYT Veracyte	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Underweight	$47.00 ➝ $44.00

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$0.98 per share	N/A
DNLI Denali Therapeutics	$330.53M	10.77	N/A	N/A	$5.22 per share	4.27
GRAL GRAIL	$147.17M	24.39	N/A	N/A	$56.93 per share	1.41
VCYT Veracyte	$517.15M	6.61	$1.49 per share	28.55	$17.27 per share	2.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$206.69M	-$1.16	N/A	N/A	N/A	N/A	-106.15%	-79.82%	11/9/2026 (Estimated)
DNLI Denali Therapeutics	-$512.54M	-$2.84	N/A	N/A	N/A	N/A	-55.27%	-44.24%	11/5/2026 (Estimated)
GRAL GRAIL	-$408.35M	-$9.75	N/A	N/A	N/A	-236.95%	-15.88%	-14.02%	11/11/2026 (Estimated)
VCYT Veracyte	$66.35M	$1.41	30.16	27.62	N/A	20.37%	9.26%	8.61%	11/3/2026 (Estimated)

Latest ANNX, DNLI, VCYT, and GRAL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ANNX Annexon	-$0.2388	-$0.28	-$0.0412	-$0.28	$6.50 million	N/A
8/6/2026	Q2 2026	DNLI Denali Therapeutics	-$0.5131	-$0.68	-$0.1670	-$0.68	$2.15 million	$3.60 million
8/5/2026	Q2 2026	GRAL GRAIL	-$2.66	-$2.56	+$0.10	-$2.56	$42.39 million	$44.69 million
7/30/2026	Q2 2026	VCYT Veracyte	$0.4103	$0.54	+$0.1297	$0.31	$144.59 million	$150.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
GRAL GRAIL	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	5.53	5.53
DNLI Denali Therapeutics	0.01	8.37	8.32
GRAL GRAIL	N/A	10.95	10.95
VCYT Veracyte	N/A	9.16	8.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
DNLI Denali Therapeutics	92.92%
GRAL GRAIL	N/A
VCYT Veracyte	N/A

Insider Ownership

Company	Insider Ownership
ANNX Annexon	10.31%
DNLI Denali Therapeutics	9.70%
GRAL GRAIL	1.83%
VCYT Veracyte	1.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	60	189.58 million	170.03 million	Optionable
DNLI Denali Therapeutics	430	159.85 million	144.34 million	Optionable
GRAL GRAIL	1,360	44.67 million	43.85 million	Optionable
VCYT Veracyte	790	80.39 million	79.11 million	Optionable

ANNX, DNLI, VCYT, and GRAL Headlines

Recent News About These Companies

Veracyte (NASDAQ:VCYT) Stock Price Down 4.5% After Insider Selling

1 hour ago | americanbankingnews.com

Insider Selling: Veracyte (NASDAQ:VCYT) EVP Sells 3,254 Shares

September 5 at 7:22 AM | insidertrades.com

Veracyte (NASDAQ:VCYT) EVP Sells 3,254 Shares of Stock

September 4 at 9:06 PM | marketbeat.com

Veracyte (NASDAQ:VCYT) CFO Sells 3,652 Shares

September 4 at 9:06 PM | marketbeat.com

Phillip Febbo Sells 13,110 Shares of Veracyte (NASDAQ:VCYT) Stock

September 4 at 9:06 PM | marketbeat.com

Veracyte (NASDAQ:VCYT) Shares Down 4.5% After Insider Selling

September 4 at 1:19 PM | marketbeat.com

Muna Bhanji Sells 1,864 Shares of Veracyte (NASDAQ:VCYT) Stock

September 4 at 7:07 AM | insidertrades.com

Insider Selling: Veracyte (NASDAQ:VCYT) Director Sells 1,864 Shares of Stock

September 3 at 5:22 PM | marketbeat.com

22,291 Shares in Veracyte, Inc. $VCYT Acquired by Man Group plc

September 3 at 4:47 AM | marketbeat.com

The Manufacturers Life Insurance Company Purchases New Stake in Veracyte, Inc. $VCYT

September 3 at 4:40 AM | marketbeat.com

Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

September 1, 2026 | globenewswire.com

Veracyte, Inc. $VCYT Shares Sold by Moore Capital Management LP

September 1, 2026 | marketbeat.com

Wellington Management Group LLP Lowers Position in Veracyte, Inc. $VCYT

September 1, 2026 | marketbeat.com

161,973 Shares in Veracyte, Inc. $VCYT Bought by Corient Private Wealth LP

August 31, 2026 | marketbeat.com

Alyeska Investment Group L.P. Lowers Stock Position in Veracyte, Inc. $VCYT

August 31, 2026 | marketbeat.com

269,806 Shares in Veracyte, Inc. $VCYT Purchased by Jupiter Topco LLC

August 30, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Takes $1.58 Million Position in Veracyte, Inc. $VCYT

August 30, 2026 | marketbeat.com

437,604 Shares in Veracyte, Inc. $VCYT Purchased by Bank of New York Mellon Corp

August 30, 2026 | marketbeat.com

Legal & General Group Plc Invests $50.40 Million in Veracyte, Inc. $VCYT

August 29, 2026 | marketbeat.com

Formula Growth Ltd. Purchases Shares of 27,000 Veracyte, Inc. $VCYT

August 28, 2026 | marketbeat.com

Analyzing Wesana Health (OTCMKTS:WSNAF) & Veracyte (NASDAQ:VCYT)

August 28, 2026 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX, DNLI, VCYT, and GRAL Company Descriptions

Annexon NASDAQ:ANNX

$4.87 +0.03 (+0.62%)

As of 09/4/2026 04:00 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Denali Therapeutics NASDAQ:DNLI

$22.28 -0.52 (-2.28%)

As of 09/4/2026 04:00 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

GRAIL NASDAQ:GRAL

$80.34 -0.28 (-0.35%)

As of 09/4/2026 04:00 PM Eastern

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Veracyte NASDAQ:VCYT

$42.53 -2.14 (-4.79%)

As of 09/4/2026 04:00 PM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANNX, DNLI, VCYT, and GRAL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANNX, DNLI, VCYT, and GRAL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANNX, DNLI, VCYT, and GRAL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX, DNLI, VCYT, and GRAL Company Descriptions

Annexon NASDAQ:ANNX

Denali Therapeutics NASDAQ:DNLI

GRAIL NASDAQ:GRAL

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANNX, DNLI, VCYT, and GRAL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANNX, DNLI, VCYT, and GRAL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANNX, DNLI, VCYT, and GRAL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX, DNLI, VCYT, and GRAL Company Descriptions

Annexon NASDAQ:ANNX

Denali Therapeutics NASDAQ:DNLI

GRAIL NASDAQ:GRAL

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools